Standard BioTools Inc. (LAB) stock
LABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 12/3087% below fair value
$0.65+0.01 (+1.31%)
Close on Nov 12, 2026Market cap $255.73MP/E 3.0Yield –
Standard BioTools cash
Cash and short-term investments held at the end of each period.
Standard BioTools's cash was $476.72M at Jun 30, 2026. For fiscal 2025 it was $187.58M, down 36.4% from the year before. Over ten years it grew 7.0% a year on average. The highest annual figure on record is $294.96M in fiscal 2024.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $187.58M | -36.4% |
| FY2024 | Dec 31, 2024 | $294.96M | +155.0% |
| FY2023 | Dec 31, 2023 | $115.69M | -30.6% |
| FY2022 | Dec 31, 2022 | $166.80M | +466.1% |
| FY2021 | Dec 31, 2021 | $29.47M | -57.6% |
| FY2020 | Dec 31, 2020 | $69.54M | +14.5% |
| FY2019 | Dec 31, 2019 | $60.71M | -36.4% |
| FY2018 | Dec 31, 2018 | $95.40M | +51.1% |
| FY2017 | Dec 31, 2017 | $63.14M | +6.2% |
| FY2016 | Dec 31, 2016 | $59.43M | -37.4% |
| FY2015 | Dec 31, 2015 | $94.97M | -17.6% |
| FY2014 | Dec 31, 2014 | $115.30M | +36.7% |
| FY2013 | Dec 31, 2013 | $84.34M | +5.4% |
| FY2012 | Dec 31, 2012 | $80.01M | +49.6% |
| FY2011 | Dec 31, 2011 | $53.47M | +834.2% |
| FY2010 | Dec 31, 2010 | $5.72M | -60.8% |
| FY2009 | Dec 31, 2009 | $14.60M | -17.9% |
| FY2008 | Dec 27, 2008 | $17.80M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $476.72M | +98.9% |
| Q1 FY2026 | Mar 31, 2026 | $455.18M | +74.6% |
| Q4 FY2025 | Dec 31, 2025 | $187.58M | -36.4% |
| Q3 FY2025 | Sep 30, 2025 | $194.90M | -47.0% |
| Q2 FY2025 | Jun 30, 2025 | $239.67M | -39.5% |
| Q1 FY2025 | Mar 31, 2025 | $260.65M | -43.8% |
| Q4 FY2024 | Dec 31, 2024 | $294.96M | +155.0% |
| Q3 FY2024 | Sep 30, 2024 | $367.62M | +183.6% |
| Q2 FY2024 | Jun 30, 2024 | $396.00M | +176.7% |
| Q1 FY2024 | Mar 31, 2024 | $463.57M | +198.4% |
| Q4 FY2023 | Dec 31, 2023 | $115.69M | -30.6% |
| Q3 FY2023 | Sep 30, 2023 | $129.65M | -30.4% |
| Q2 FY2023 | Jun 30, 2023 | $143.10M | -32.6% |
| Q1 FY2023 | Mar 31, 2023 | $155.33M | +401.1% |
| Q4 FY2022 | Dec 31, 2022 | $166.80M | +466.1% |
| Q3 FY2022 | Sep 30, 2022 | $186.18M | +514.0% |
| Q2 FY2022 | Jun 30, 2022 | $212.23M | +565.7% |
| Q1 FY2022 | Mar 31, 2022 | $31.00M | -38.9% |
| Q4 FY2021 | Dec 31, 2021 | $29.47M | -57.6% |
| Q3 FY2021 | Sep 30, 2021 | $30.33M | -58.7% |
| Q2 FY2021 | Jun 30, 2021 | $31.88M | -31.4% |
| Q1 FY2021 | Mar 31, 2021 | $50.76M | +2.4% |
| Q4 FY2020 | Dec 31, 2020 | $69.54M | +14.5% |
| Q3 FY2020 | Sep 30, 2020 | $73.36M | +13.1% |
| Q2 FY2020 | Jun 30, 2020 | $46.47M | -34.5% |
| Q1 FY2020 | Mar 31, 2020 | $49.56M | -34.0% |
| Q4 FY2019 | Dec 31, 2019 | $60.71M | -36.4% |
| Q3 FY2019 | Sep 30, 2019 | $64.84M | +81.0% |
| Q2 FY2019 | Jun 30, 2019 | $70.94M | +75.5% |
| Q1 FY2019 | Mar 31, 2019 | $75.13M | +59.0% |
| Q4 FY2018 | Dec 31, 2018 | $95.40M | +51.1% |
| Q3 FY2018 | Sep 30, 2018 | $35.83M | -42.6% |
| Q2 FY2018 | Jun 30, 2018 | $40.42M | -3.8% |
| Q1 FY2018 | Mar 31, 2018 | $47.25M | -6.0% |
| Q4 FY2017 | Dec 31, 2017 | $63.14M | +6.2% |
| Q3 FY2017 | Sep 30, 2017 | $62.37M | -12.5% |
| Q2 FY2017 | Jun 30, 2017 | $42.03M | – |
| Q1 FY2017 | Mar 31, 2017 | $50.28M | – |
| Q4 FY2016 | Dec 31, 2016 | $59.43M | – |
| Q3 FY2016 | Sep 30, 2016 | $71.25M | – |
See a number that looks wrong?